|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM113152248 |
| 003 |
DE-627 |
| 005 |
20231222163254.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0378.xml
|
| 035 |
|
|
|a (DE-627)NLM113152248
|
| 035 |
|
|
|a (NLM)11411099
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Shimizu, K
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical efficacy of treatment with low-dose flutamide in maximum androgen blockade therapy
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.07.2001
|
| 500 |
|
|
|a Date Revised 24.11.2016
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a To prevent treatment withdrawal due to flutamide-induced liver dysfunction, we performed maximum androgen blockade (MAB) therapy by combining a luteinizing hormone-releasing hormone agonist or orchiectomy with low-dose flutamide (125 mg x 2/day) in patients with prostate cancer. In this study, the efficacy, adverse effects such as hepatotoxicity, and compliance were compared retrospectively between 35 patients who received low-dose flutamide therapy (1995-1999) and 27 patients who received flutamide at its ordinary dose (125 mg x 3/day). No significant difference was observed in the response rate (> or = PR) as determined from the prostate-specific antigen parameter (p = 0.6211) or the incidence of hepatotoxicity based on the aspartate aminotransferase and alanine aminotransferase levels. However, flutamide withdrawal due to liver dysfunction was less frequent in the low-dose group (2.9%) than in the ordinary dose group (18.5%) (p = 0.0386). MAB therapy using low-dose flutamide is expected to prevent the reduction in the compliance due to side effects and to improve the long-term prognosis in patients with prostate cancer, who are mostly elderly individuals
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Androgen Antagonists
|2 NLM
|
| 650 |
|
7 |
|a Gonadotropin-Releasing Hormone
|2 NLM
|
| 650 |
|
7 |
|a 33515-09-2
|2 NLM
|
| 650 |
|
7 |
|a Flutamide
|2 NLM
|
| 650 |
|
7 |
|a 76W6J0943E
|2 NLM
|
| 650 |
|
7 |
|a Prostate-Specific Antigen
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.77
|2 NLM
|
| 700 |
1 |
|
|a Kiyohara, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakayama, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fujii, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hosomi, M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 47(2001), 4 vom: 24. Apr., Seite 251-5
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:47
|g year:2001
|g number:4
|g day:24
|g month:04
|g pages:251-5
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 47
|j 2001
|e 4
|b 24
|c 04
|h 251-5
|